Compare BNGO & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | CTXR |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 19.8M |
| IPO Year | 2018 | N/A |
| Metric | BNGO | CTXR |
|---|---|---|
| Price | $1.58 | $0.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $6.33 | $6.00 |
| AVG Volume (30 Days) | 146.0K | ★ 1.6M |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,720,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.56 | $147.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.45 | $0.63 |
| 52 Week High | $15.60 | $3.82 |
| Indicator | BNGO | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 42.93 |
| Support Level | $1.47 | $0.76 |
| Resistance Level | $1.64 | $0.99 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 72.06 | 48.73 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.